Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb’s Megace

Executive Summary

Use of Megace (megestrol acetate) oral suspension and 250 mg tablets for the treatment of cachexia is the scheduled topic for FDA's Antiviral Drugs Advisory Committee meeting Feb. 18. Megace is approved for the palliative treatment of advanced carcinoma of the breast or endometrium. The meeting will be held at FDA's Parklawn Building, Rockville, Md., Conference Rooms D & E.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel